Literature DB >> 35535694

Clinical and microbiologic outcomes of central nervous system cryptococcosis: Re-examining the need for a 2-week cerebrospinal fluid analysis.

Zachary A Yetmar1, Nischal Ranganath1, Maria A Mendoza1, Raymund R Razonable1,2.   

Abstract

BACKGROUND: Cryptococcus spp. infection involving the central nervous system (CNS) is associated with poor outcomes. Current guidelines recommend repeating a cerebrospinal fluid (CSF) fungal culture after 2 weeks of treatment to evaluate for clearance. However, this practice has not clearly been associated with outcomes.
OBJECTIVES: We sought to assess the relationship between CSF fungal clearance at 2 weeks and 12-month mortality in patients with CNS cryptococcosis.
METHODS: This is a retrospective cohort study from 2011 to 2020 of patients with CNS cryptococcosis. Factors associated with 12-month mortality were assessed with Fisher's exact test for categorical variables and Mann-Whitney test for continuous variables.
RESULTS: Among 51 patients with CNS cryptococcosis, 42 (82.4%) were initially CSF culture positive. Among 27 patients with follow-up CSF culture at 2 weeks, 6 (22.2%) had a positive result. Factors associated with a positive CSF culture at 2 weeks were an initial CSF cryptococcal antigen titre ≥1:2560, fungaemia, and an elevated intracranial pressure requiring therapeutic lumbar punctures. The 12-month mortality rate was 33.3%, and this was significantly associated with baseline fungaemia, extra-CNS cryptococcal involvement and requirement of intensive care unit level of care. Lack of CSF culture clearance by 2 weeks was not associated with 12-month mortality.
CONCLUSIONS: CNS cryptococcosis has a high mortality rate. A markedly elevated CSF cryptococcal antigen, and opening CSF pressure was associated with lack of CSF culture clearance at 2 weeks of treatment. Severe disseminated disease and cryptococcemia were associated with 12-month mortality.
© 2022 Wiley-VCH GmbH.

Entities:  

Keywords:  zzm321990Cryptococcuszzm321990; central nervous system; fungaemia; lumbar puncture; mortality

Mesh:

Substances:

Year:  2022        PMID: 35535694      PMCID: PMC9233060          DOI: 10.1111/myc.13467

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.931


  26 in total

1.  Cryptococcosis in apparently immunocompetent patients.

Authors:  G Lui; N Lee; M Ip; K W Choi; Y K Tso; E Lam; S Chau; R Lai; C S Cockram
Journal:  QJM       Date:  2006-02-27

Review 2.  Lumbar puncture in patients using anticoagulants and antiplatelet agents.

Authors:  Renan Domingues; Gustavo Bruniera; Fernando Brunale; Cristóvão Mangueira; Carlos Senne
Journal:  Arq Neuropsiquiatr       Date:  2016-08       Impact factor: 1.420

3.  Clinical features and Outcomes of Cryptococcemia patients with and without HIV infection.

Authors:  Handan Zhao; Minghan Zhou; Qing Zheng; Mingjian Zhu; Zongxing Yang; Caiqin Hu; Lijun Xu
Journal:  Mycoses       Date:  2021-03-02       Impact factor: 4.377

4.  Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome.

Authors:  Christina C Chang; Afton A Dorasamy; Bernadett I Gosnell; Julian H Elliott; Tim Spelman; Saleha Omarjee; Vivek Naranbhai; Yacoob Coovadia; Thumbi Ndung'u; Mohamed-Yunus S Moosa; Sharon R Lewin; Martyn A French
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

5.  Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures.

Authors:  Tihana Bicanic; Annemarie E Brouwer; Graeme Meintjes; Kevin Rebe; Direk Limmathurotsakul; Wirongrong Chierakul; Praprit Teparrakkul; Angela Loyse; Nicholas J White; Robin Wood; Shabbar Jaffar; Thomas Harrison
Journal:  AIDS       Date:  2009-03-27       Impact factor: 4.177

6.  Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression.

Authors:  Hsin-Yun Sun; Barbara D Alexander; Shirish Huprikar; Graeme N Forrest; Didier Bruno; G Marshall Lyon; Dannah Wray; Leonard B Johnson; Costi D Sifri; Raymund R Razonable; Michele I Morris; Valentina Stosor; Marilyn M Wagener; Nina Singh
Journal:  Clin Infect Dis       Date:  2014-09-09       Impact factor: 9.079

7.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

8.  Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis.

Authors:  Justin Beardsley; Marcel Wolbers; Freddie M Kibengo; Abu-Baker M Ggayi; Anatoli Kamali; Ngo Thi Kim Cuc; Tran Quang Binh; Nguyen Van Vinh Chau; Jeremy Farrar; Laura Merson; Lan Phuong; Guy Thwaites; Nguyen Van Kinh; Pham Thanh Thuy; Wirongrong Chierakul; Suwatthiya Siriboon; Ekkachai Thiansukhon; Satrirat Onsanit; Watthanapong Supphamongkholchaikul; Adrienne K Chan; Robert Heyderman; Edson Mwinjiwa; Joep J van Oosterhout; Darma Imran; Hasan Basri; Mayfong Mayxay; David Dance; Prasith Phimmasone; Sayaphet Rattanavong; David G Lalloo; Jeremy N Day
Journal:  N Engl J Med       Date:  2016-02-11       Impact factor: 91.245

9.  Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis.

Authors:  Melissa A Rolfes; Joshua Rhein; Charlotte Schutz; Kabanda Taseera; Henry W Nabeta; Kathy Huppler Hullsiek; Andrew Akampuira; Radha Rajasingham; Abdu Musubire; Darlisha A Williams; Friedrich Thienemann; Paul R Bohjanen; Conrad Muzoora; Graeme Meintjes; David B Meya; David R Boulware
Journal:  Open Forum Infect Dis       Date:  2015-12-28       Impact factor: 3.835

10.  Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.

Authors:  J Peter Donnelly; Sharon C Chen; Carol A Kauffman; William J Steinbach; John W Baddley; Paul E Verweij; Cornelius J Clancy; John R Wingard; Shawn R Lockhart; Andreas H Groll; Tania C Sorrell; Matteo Bassetti; Hamdi Akan; Barbara D Alexander; David Andes; Elie Azoulay; Ralf Bialek; Robert W Bradsher; Stephane Bretagne; Thierry Calandra; Angela M Caliendo; Elio Castagnola; Mario Cruciani; Manuel Cuenca-Estrella; Catherine F Decker; Sujal R Desai; Brian Fisher; Thomas Harrison; Claus Peter Heussel; Henrik E Jensen; Christopher C Kibbler; Dimitrios P Kontoyiannis; Bart-Jan Kullberg; Katrien Lagrou; Frédéric Lamoth; Thomas Lehrnbecher; Jurgen Loeffler; Olivier Lortholary; Johan Maertens; Oscar Marchetti; Kieren A Marr; Henry Masur; Jacques F Meis; C Orla Morrisey; Marcio Nucci; Luis Ostrosky-Zeichner; Livio Pagano; Thomas F Patterson; John R Perfect; Zdenek Racil; Emmanuel Roilides; Marcus Ruhnke; Cornelia Schaefer Prokop; Shmuel Shoham; Monica A Slavin; David A Stevens; George R Thompson; Jose A Vazquez; Claudio Viscoli; Thomas J Walsh; Adilia Warris; L Joseph Wheat; P Lewis White; Theoklis E Zaoutis; Peter G Pappas
Journal:  Clin Infect Dis       Date:  2020-09-12       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.